Results 211 to 220 of about 117,510 (294)

Enfortumab vedotin plus pembrolizumab in treatment‐naïve metastatic urothelial carcinoma patients: An Austrian real‐world analysis

open access: yesInternational Journal of Cancer, Volume 158, Issue 6, Page 1654-1665, 15 March 2026.
What's new? New antibody‐drug conjugates (ADCs) and immunotherapies have helped expand treatment options for urothelial carcinoma (UC). Clinical trials suggest that the ADC enfortumab vedotin (EV) and the immunotherapeutic agent pembrolizumab, when used in combination, are especially effective against UC.
Dora Niedersuess‐Beke   +30 more
wiley   +1 more source

An unusual cause of fatal pulmonary embolism: A case report. [PDF]

open access: yesRespir Med Case Rep
Cmor N   +4 more
europepmc   +1 more source

Insect‐Derived Bioactives for Glycemic Control and Gut Health: A Review

open access: yesFood Frontiers, Volume 7, Issue 2, March 2026.
Insect‐derived bioactive compounds (e.g., peptides, polysaccharides) effectively regulate blood glucose through dual mechanisms: directly inhibiting carbohydrate‐digesting enzymes and glucose transporters, and indirectly modulating gut microbiota to enhance intestinal barrier integrity.
Chaoyi Lv   +5 more
wiley   +1 more source

Incidentalomas discoveries during staging and surveillance for colorectal cancer patients. [PDF]

open access: yesMedicine (Baltimore)
Liu XR   +5 more
europepmc   +1 more source

Non‐Functional Paraganglioma of the Urinary Bladder: A Rare Cause of Bladder Tumor

open access: yesIJU Case Reports, Volume 9, Issue 2, March 2026.
ABSTRACT Introduction Paragangliomas of the urinary bladder (PUBs) are rare neuroendocrine tumors, representing less than 0.06% of all bladder neoplasms. While most are functional and associated with catecholamine excess, approximately 15% are non‐functional, often presenting asymptomatically and discovered incidentally.
Matt Wainstein   +4 more
wiley   +1 more source

Cancer Comorbidities: Clinical Impacts, Mechanistic Insights, and Management Strategies

open access: yesMedComm – Oncology, Volume 5, Issue 1, March 2026.
This review focuses on cancer comorbidities, examining their clinical impacts and mechanistic insights. It further examines key management challenges, including evidence gaps, the lack of precise assessment tools, limited management frameworks, and underdeveloped multidisciplinary collaborations.
Taoxing Peng   +15 more
wiley   +1 more source

Home - About - Disclaimer - Privacy